Rodolfo Montironi

TL;DR: A literature search was performed using MEDLINE/PubMed and scientific congress databases using the terms ‘BRAF,’ ‘mutation, and ‘cancer/tumor.’ These results were filtered to include diagnostic tests for determining BRAF mutation status as mentioned in this paper.

TL;DR: The proceedings of the 2nd International Consultation on Bladder Cancer, which included a ‘Pathology of Bladder cancer Work Group,’ have recently been published; herein, a summary of developments and consensus relevant to the practicing pathologist is provided as discussed by the authors.

TL;DR: This study illustrated the pathogenic and prognostic role of EMT in RCC, and reconstructed, by literature analysis, the different pathways implicated in the EMT process, thus supporting the rational for future EMT-directed therapeutic approaches for RCC patients.

TL;DR: In this paper, the authors describe the active or ongoing clinical trials involving Programmed Death Ligand 1 (PD-L1), Programmed death receptor 1(PD-1) and Cytotoxic-T Lymphocyte Antigen 4 (CTLA 4) inhibitors in urothelial carcinoma focusing their attention on the developing new immune agents and combination strategies with immune-checkpoint inhibitors.

TL;DR: Better understanding of how epigenetic change regulates the progression of prostate cancer and the interaction between epigenetic and genetic modulators driving NEPC may help develop a better risk stratification and more effective treatment regimens for prostate cancer patients.